TARGET AUDIENCE
The audience that will benefit from this education are hematology/oncology, cardio-oncology, and cardiology clinicians (physicians, nurse practitioners, physician assistants, nurses, and fellows).

PROGRAM OVERVIEW
An engaging three-part podcast series designed to empower oncology nurses and advanced practice providers with the knowledge and practical tools needed to support patients with chronic lymphocytic leukemia (CLL) undergoing treatment with BTK inhibitors. Each episode brings clinical insights and evidence-based strategies to the forefront, helping nurses navigate the complexities of the BTK inhibitor therapy from both a pharmacological and patient care perspective.

Upon completion of this activity, the learners should be able to:

• Differentiate between the clinical profiles of various BTK inhibitors used in CLL treatment, including long-term data
• Identify and compare the CV risk profiles associated with different BTK inhibitors in CLL therapy
• Develop comprehensive management plans to prevent, mitigate, and manage CV complications in patients with CLL treated with BTK inhibitors, while incorporating recent clinical data and updated guidelines
• Incorporate patient perspectives and multidisciplinary approaches into treatment decisions and long-term management in patients with CLL

FACULTY

Anecita Fadol, PhD, APRN, FNP, FAANP, FHKAN (Hon.), FAAN
Department of Nursing, Division of SrVP and Chief Nursing Officer
MD Anderson Cancer Center
Houston, Texas

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Research Associate, Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Lisa Hodzon, PhD, APRN, AOCNP
Advanced Registered Nurse Practitioner, APP Lead
Moffitt Cancer Center
Tampa, Florida

Hasana O’Neal, MHS, PA-C
Cardiology Physician Assistant
MD Anderson Cancer Center
Houston, Texas

PLANNING COMMITTEE

Anecita Fadol, PhD, APRN, FNP, FAANP, FHKAN (Hon.), FAAN
Department of Nursing, Division of SrVP and Chief Nursing Officer
MD Anderson Cancer Center
Houston, Texas

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Research Associate, Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Lisa Hodzon, PhD, APRN, AOCNP
Advanced Registered Nurse Practitioner, APP Lead
Moffitt Cancer Center
Tampa, Florida

Hasana O’Neal, MHS, PA-C
Cardiology Physician Assistant
MD Anderson Cancer Center
Houston, Texas

This activity is jointly provided by The France Foundation and the Internation Cardio-Oncology Society.

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the International Cardio-Oncology Society. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The France Foundation designates this activity for 1.0 contact hours.

Physician Assistants
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 6/29/26. PAs should only claim credit commensurate with the extent of their participation.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) and International Cardio-Oncology Society (IC-OS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

TFF and IC-OS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-OS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by independent medical educational grants from AstraZeneca and Lilly.

The France Foundation and the International Cardio-Oncology Society present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the International Cardio-Oncology Society, and the commercial supporters assume no liability for the information herein.

Copyright © 2025 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation’s Privacy Policy can be viewed at www.francefoundation.com/privacy.